Your browser is no longer supported. Please, upgrade your browser.
Settings
GILD Gilead Sciences, Inc. daily Stock Chart
GILD [NASD]
Gilead Sciences, Inc.
IndexS&P 500 P/E6.79 EPS (ttm)9.94 Insider Own0.40% Shs Outstand1.31B Perf Week-2.24%
Market Cap88.24B Forward P/E8.96 EPS next Y7.54 Insider Trans-11.21% Shs Float1.30B Perf Month-1.93%
Income13.50B PEG- EPS next Q2.26 Inst Own77.90% Short Float1.04% Perf Quarter-8.02%
Sales30.39B P/S2.90 EPS this Y-16.50% Inst Trans0.32% Short Ratio1.27 Perf Half Y-16.01%
Book/sh14.36 P/B4.70 EPS next Y-8.59% ROA25.60% Target Price79.06 Perf Year-24.15%
Cash/sh9.16 P/C7.37 EPS next 5Y-4.81% ROE83.50% 52W Range64.88 - 100.48 Perf YTD-5.00%
Dividend2.08 P/FCF6.55 EPS past 5Y41.20% ROI31.00% 52W High-32.81% Beta1.14
Dividend %3.08% Quick Ratio2.00 Sales past 5Y29.40% Gross Margin86.00% 52W Low4.05% ATR1.03
Employees9000 Current Ratio2.20 Sales Q/Q-13.90% Oper. Margin58.00% RSI (14)40.24 Volatility1.21% 1.39%
OptionableYes Debt/Eq1.39 EPS Q/Q-26.40% Profit Margin44.40% Rel Volume0.57 Prev Close67.49
ShortableYes LT Debt/Eq1.39 EarningsFeb 07 AMC Payout18.30% Avg Volume10.67M Price67.51
Recom2.30 SMA20-1.81% SMA50-2.99% SMA200-10.20% Volume6,037,090 Change0.03%
Mar-09-17Resumed UBS Neutral $118 → $72
Feb-08-17Downgrade Citigroup Buy → Neutral
Nov-14-16Initiated Stifel Buy $100
Nov-08-16Initiated Mizuho Buy $88
Nov-02-16Reiterated RBC Capital Mkts Outperform $95 → $90
Oct-25-16Reiterated Jefferies Buy $93 → $95
Oct-03-16Reiterated RBC Capital Mkts Outperform $105 → $95
Sep-27-16Downgrade Leerink Partners Outperform → Mkt Perform $112 → $94
Sep-12-16Initiated Berenberg Buy $112
Sep-06-16Upgrade Jefferies Hold → Buy
Jul-29-16Downgrade Argus Buy → Hold
Jul-26-16Reiterated RBC Capital Mkts Outperform $120 → $105
Jul-26-16Downgrade Needham Buy → Hold
Jun-01-16Initiated Gabelli & Co Buy $109
Apr-29-16Reiterated UBS Buy $130 → $118
Apr-29-16Downgrade Maxim Group Buy → Hold
Mar-16-16Reiterated Leerink Partners Outperform $130 → $127
Feb-25-16Initiated Citigroup Buy $110
Feb-12-16Reiterated Maxim Group Buy $137 → $115
Feb-03-16Reiterated RBC Capital Mkts Outperform $130 → $120
Mar-24-17 08:04AM  The Best-Case Scenario for Gilead Sciences, Inc. at Motley Fool
Mar-23-17 10:57AM  Biotechs Back in the Doghouse After Failed Rally at Investopedia
Mar-22-17 04:23PM  My 3 Worst-Performing Stocks -- and Why I Still Own Them at Motley Fool
09:30AM  Zacks Investment Ideas feature highlights: Nasdaq Biotechnology Index, Gilead, Valeant Pharma, Celgene and Amgen
Mar-21-17 04:22PM  Mylan Receives Tentative Approval from FDA for HIV Therapy
04:00PM  British Columbia lists EPCLUSA on public drug plan to treat all six genotypes of chronic hepatitis C infection CNW Group
08:52AM  Ionis Pharmaceuticals Valuation Compared to Its Peers
Mar-20-17 04:22PM  3 Stocks That Are Ridiculously Cheap Right Now at Motley Fool
01:08PM  Gilead Sciences: Wait, Its Pipeline Isn't Completely Barren? at Barrons.com
12:25PM  EPCLUSA, to treat all six genotypes of chronic hepatitis C infection, added to the Liste des m├ędicaments de la RAMQ CNW Group
10:06AM  Why Biotech Stock Gilead (GILD) Could Be a Value Trap
09:50AM  Jefferies Has 4 Red-Hot Biotech and Pharmaceutical Stocks to Buy Now
Mar-17-17 11:03AM  3 Drug Stocks With Some of the Highest Profit Margins at Motley Fool
Mar-16-17 03:40PM  3 Numbers That Make Gilead Sciences, Inc. Look Cheaper Than It Really Is at Motley Fool
08:02AM  Dividend Stocks Hedge Funds Are Betting On at Insider Monkey
07:08AM  [$$] Celgene Shows Savvy as Gilead Keeps Backsliding at Barrons.com
Mar-15-17 05:40PM  Forget Gilead, Buy These Small-Cap Biotech Stocks Instead
09:54AM  Wait, Gilead Might Actually Hit Its 1st Quarter Numbers?!?! at Barrons.com
08:03AM  3 Reasons Why Gilead Sciences Will Buy Incyte -- and 1 Reason Why It Won't at Motley Fool
Mar-14-17 10:55AM  Gilead Looking To Buy Incyte? It Makes Sense
07:36AM  Johnson & Johnsons Pharmaceuticals Segment
05:18AM  This titanic stock market has that sinking feeling at MarketWatch
Mar-13-17 06:20PM  After-hours buzz: VRX, INCY, COUP & more at CNBC
05:27PM  Executive Chairman Slashes Stake in Gilead Sciences
04:48PM  Incyte Spikes To Record High On Rumors Gilead Could Acquire It
03:42PM  Is Incyte For Sale? at Investopedia
02:08PM  Biotech stocks are turning bullishhere's how to profit
10:22AM  Gilead Sciences: Is an Incyte Deal 'Reasonable'? at Barrons.com
09:49AM  3 Underdog Stocks We're Watching Closely at Motley Fool
06:00AM  Barclays Lists 5 Steps to Boost GILD Stock
Mar-12-17 06:42AM  3 Healthcare Stocks That Are Looking Cheap at Motley Fool
Mar-11-17 11:41AM  Which Biotech Is the Best Dividend Stock? at Motley Fool
12:35AM  [$$] Resisting the Allure of Gilead at Barrons.com
Mar-10-17 05:01PM  The Hot Stock: Incyte Soars 8.1% on Gilead Takeover Speculation at Barrons.com
04:30PM  Incyte Pops on Continued Gilead Takeout Speculation
02:33PM  Adam Feuerstein Weighs In On Novo-GBT Rumors, Undue Sarepta Volatility, Unprofitable Business Of Curing Disease
02:13PM  Dear Gilead: Buy Something Anything Analyst Pleads
02:13PM  Analyst Pleads With Gilead To Buy And It May Have Worked
01:12PM  AbbVie Stock Upgraded: What You Need to Know at Motley Fool
12:37PM  Gilead Sciences: Just Any Deal Won't Do at Barrons.com
11:46AM  How Gilead Is Paying The Price For Actually Curing A Disease
11:34AM  Is Gilead Sciences Worthy of Your Portfolio? at Insider Monkey
11:32AM  Adam Feuerstein Talks Vulnerable Pharmaceuticals, Drug Pricing Under Trump
10:30AM  Major Biotechs See a Retreat in Short Interest
07:51AM  How Incyte Stock Became a Bull Market Star for Biotech Investors
Mar-09-17 04:55PM  Will Merck, Glaxo Undercut Gilead's Next 'Mount Everest' Drug?
04:31PM  Momo Dives Despite Price Target Hike; UBS Initiates Biotechs; Mercury Is A Buy
04:21PM  Will Gilead Sciences Net a $270 Million Windfall? at Motley Fool
01:40PM  Drugs, travel, jewelry and social media in the blitz
01:25PM  What Does Gilead Need? Stable HCV Scripts and "a String of Pearls" at Barrons.com
12:38PM  3 Biotech Stocks to Buy Nowand 1 to Dump ASAP at Barrons.com
11:02AM  Gilead: "Stuck Between A Rock And A Hard Place?" at Barrons.com
10:44AM  I Was Wrong About Gilead Sciences at Motley Fool
Mar-08-17 04:22PM  This Pharma Firm Is Beating The Pack In Getting Drugs To Market
07:25AM  Are Hedge Funds Turning Bearish on Healthcare Stocks? at Insider Monkey
Mar-07-17 03:50PM  The healthcare industry is starting to turn on itself as pressure over drug prices heats up
03:04PM  3 Biotech Stocks You Don't Have to Babysit at Motley Fool
12:38PM  Pharma, Biotech Stocks Fall on Trump Tweets, GOP Health Care Plan
08:04AM  Here's Why the Best Is Yet to Come for Gilead Sciences, Inc. at Motley Fool
Mar-06-17 02:35PM  Jeff Auxier Invests in Gilead, Wells Fargo, Apple
01:29PM  Bristol-Myers Squibb: Don't Get Your Hopes Up at Barrons.com
01:10PM  RBC Hints At Potential M&A For Kite Pharma
Mar-05-17 03:03PM  How Are Drug Prices Determined? at Motley Fool
Mar-03-17 04:13PM  Gilead Executive Says Pharmacy Benefit Managers Keep Prices High
02:49PM  Is Gilead's Guidance Conservative? at Barrons.com
01:04PM  GILEAD SCIENCES INC Financials
11:11AM  2 Reasons Behind Sarepta Therapeutics Inc.'s 6.9% February Jump at Motley Fool
Mar-02-17 09:30AM  Zacks Industry Outlook Highlights: Sanofi, AstraZeneca, Novo Nordisk, Gilead Sciences and Valeant Pharmaceuticals International
07:37AM  How Gileads Other Products Fared in 2016
Mar-01-17 06:43PM  Pricing to Remain Pharma Headline Risk in 2017
06:08PM  Jerome Dodson Adds to 9 Positions in 4th Quarter
11:55AM  Gilead Sciences: M&A to the Rescue? at Barrons.com
10:37AM  How Gileads Liver Disease Drugs Portfolio Performed
09:07AM  How Gileads HIV Drugs Portfolio Fared in 2016
08:06AM  Carl Icahn Takes Aim at Bristol-Myers Squibb at Motley Fool
07:38AM  How Gileads Revenue Trended in 2016
07:24AM  Biotech Stock Roundup: Kite Soars on CAR-T Data, EXEL in Immuno-Oncology Deals
Feb-28-17 05:54PM  Why Gileads Valuation Is Low Compared to Peers
05:00PM  Gilead Sciences to Present at the Barclays Global Healthcare Conference on Tuesday, March 14 Business Wire
10:15AM  Short Sellers Hike Their Bets in Major Biotechs
09:06AM  Pfizers Major Product Developments in 4Q16
09:06AM  Eli Lilly & Co.s Recent Developments
08:01AM  3 Top Healthcare Stocks to Buy Now at Motley Fool
07:37AM  Understanding Alexions Profit Margin Trend in 2017
Feb-27-17 04:26PM  GILEAD SCIENCES INC Files SEC form 10-K, Annual Report
01:21PM  Better Buy: Biogen Inc. vs. Gilead Sciences Inc. at Motley Fool
11:22AM  3 Stocks That Are Ridiculously Cheap Right Now at Motley Fool
10:00AM  SBPH: 2016 Results Sustaining Continued HBV/STING Development
08:05AM  Merck Restates 2016 Earnings, Takes $2.9B Charge at Investopedia
07:57AM  These 3 Big Pharma Stocks Are Ridiculously Cheap at Motley Fool
07:37AM  Why Vertex Expects Its Profit Margin to Rise in 2017
06:00AM  Drugmakers Eye $35B Market Amid Obesity Crisis at Investopedia
Feb-24-17 04:14PM  Gilead, AbbVie Could Perk Up On Merck's Hep C Downfall: Leerink
01:21PM  NASH Is Todd Hagopian's Top Biotech Sub-Sector For 2017 at Forbes
11:11AM  Ten Stocks That Still Look Cheap at Barrons.com
10:57AM  3 Incredibly Cheap Biotech Stocks at Motley Fool
09:20AM  7 Ultra-Cheap Value Stocks to Buy Now at Kiplinger
07:37AM  Gilead Sciences Expects a Fall in Its HCV Product Sales in 2017
Feb-23-17 05:06PM  AbbVie Stronger Bet Than Gilead, Amgen At Least Until 2020: Leerink
02:25PM  Gilead Sciences, Inc. (GILD) EPCLUSA Access To Be Provided In Ontario For Treatment Of Hepatitis C at Insider Monkey
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in Europe, North America, Asia, South America, Africa, Australia, India, and the Middle East. The company's products include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis C virus and hepatitis B virus; hematology/oncology; cardiovascular; and inflammation/respiratory diseases. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MARTIN JOHN CExecutive ChairmanMar 01Option Exercise21.5873,3331,582,1593,199,969Mar 03 06:29 PM
MOORE NICHOLAS GDirectorMar 01Option Exercise0.00173012,055Mar 03 06:03 PM
MARTIN JOHN CExecutive ChairmanMar 01Sale70.3873,3335,161,2063,126,636Mar 03 06:29 PM
WILSON GAYLE EDirectorFeb 23Option Exercise20.7133,350690,512140,836Feb 27 06:29 PM
MILLIGAN JOHN FPresident and CEOFeb 23Option Exercise21.58100,0002,157,5001,165,924Feb 27 06:13 PM
WILSON GAYLE EDirectorFeb 23Sale69.3020,3651,411,374120,471Feb 27 06:29 PM
YOUNG KEVINChief Operating OfficerFeb 10Option Exercise0.0090802,883Feb 14 12:53 PM
MARTIN JOHN CExecutive ChairmanFeb 01Option Exercise21.5873,3331,582,1593,204,429Feb 03 05:25 PM
YOUNG KEVINChief Operating OfficerFeb 01Option Exercise0.0062002,190Feb 03 05:32 PM
MARTIN JOHN CExecutive ChairmanFeb 01Sale72.5773,3335,322,0693,131,096Feb 03 05:25 PM
MARTIN JOHN CExecutive ChairmanJan 03Option Exercise21.5873,3371,582,2463,204,433Jan 05 03:39 PM
MARTIN JOHN CExecutive ChairmanJan 03Sale73.5973,3375,396,9713,131,096Jan 05 03:39 PM
MARTIN JOHN CExecutive ChairmanDec 01Option Exercise16.40100,0001,639,5003,231,096Dec 05 12:54 PM
WILSON GAYLE EDirectorDec 01Option Exercise0.002,1470107,486Dec 05 07:59 PM
MARTIN JOHN CExecutive ChairmanDec 01Sale73.33100,0007,332,8703,131,096Dec 05 12:54 PM
MADIGAN JOHN WDirectorNov 18Option Exercise20.71105,0002,174,025121,761Nov 22 02:45 PM
MADIGAN JOHN WDirectorNov 18Sale74.86105,0007,860,05916,761Nov 22 02:45 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffNov 09Sale79.0010,000790,000122,964Nov 14 01:03 PM
MARTIN JOHN CExecutive ChairmanNov 01Option Exercise16.40100,0001,639,5003,231,096Nov 03 06:10 PM
MARTIN JOHN CExecutive ChairmanNov 01Sale73.76100,0007,376,0463,131,096Nov 03 06:10 PM
MARTIN JOHN CExecutive ChairmanOct 03Option Exercise16.40100,0001,639,5003,231,096Oct 05 12:52 PM
MARTIN JOHN CExecutive ChairmanOct 03Sale77.63100,0007,762,9613,131,096Oct 05 12:52 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffSep 22Sale81.845,000409,220132,964Sep 26 04:54 PM
MILLIGAN JOHN FPresident and CEOSep 06Option Exercise20.7470,0001,451,8001,128,963Sep 08 01:35 PM
MILLIGAN JOHN FPresident and CEOSep 06Sale77.7470,0005,442,0801,058,963Sep 08 01:35 PM
MARTIN JOHN CExecutive ChairmanSep 01Option Exercise16.40100,0001,639,5003,231,096Sep 06 02:40 PM
MARTIN JOHN CExecutive ChairmanSep 01Sale77.48100,0007,748,3633,131,096Sep 06 02:40 PM
Lofton Kevin EDirectorAug 24Sale81.973,500286,8990Aug 25 05:05 PM
Carter Paul RutherfordEVP Commercial OpsAug 01Option Exercise39.132,00078,25564,305Aug 03 04:48 PM
MARTIN JOHN CExecutive ChairmanAug 01Option Exercise16.40100,0001,639,5004,119,727Aug 03 04:51 PM
MILLIGAN JOHN FPresident and CEOAug 01Option Exercise20.7470,0001,451,8001,128,963Aug 03 04:53 PM
MILLIGAN JOHN FPresident and CEOAug 01Sale70.9470,0004,965,5901,058,963Aug 03 04:53 PM
MARTIN JOHN CExecutive ChairmanAug 01Sale80.50100,0008,049,7854,019,727Aug 03 04:51 PM
Carter Paul RutherfordEVP Commercial OpsAug 01Sale79.812,000159,62062,305Aug 03 04:48 PM
Carter Paul RutherfordEVP Commercial OpsJul 31Option Exercise0.002,500063,622Aug 02 04:43 PM
MILLIGAN JOHN FPresident and CEOJul 05Option Exercise16.40112,0001,836,2401,170,963Jul 07 02:50 PM
MILLIGAN JOHN FPresident and CEOJul 05Sale84.33112,0009,444,9211,058,963Jul 07 02:50 PM
Carter Paul RutherfordEVP Commercial OpsJul 01Option Exercise24.912,00049,81063,122Jul 06 01:26 PM
MARTIN JOHN CExecutive ChairmanJul 01Option Exercise16.40100,0001,639,5004,119,727Jul 06 01:28 PM
MARTIN JOHN CExecutive ChairmanJul 01Sale84.73100,0008,472,5234,019,727Jul 06 01:28 PM
Carter Paul RutherfordEVP Commercial OpsJul 01Sale83.122,000166,25061,122Jul 06 01:26 PM
MILLIGAN JOHN FPresident and CEOJun 06Option Exercise16.40112,0001,836,2401,170,963Jun 08 06:59 PM
MILLIGAN JOHN FPresident and CEOJun 06Sale86.94112,0009,736,7791,058,963Jun 08 06:59 PM
Carter Paul RutherfordEVP Commercial OpsJun 01Option Exercise24.912,00049,81063,122Jun 03 04:46 PM
MARTIN JOHN CExecutive ChairmanJun 01Option Exercise16.40100,0001,639,5004,119,727Jun 03 04:51 PM
MARTIN JOHN CExecutive ChairmanJun 01Sale86.72100,0008,671,9504,019,727Jun 03 04:51 PM
Carter Paul RutherfordEVP Commercial OpsJun 01Sale87.022,000174,04061,122Jun 03 04:46 PM
Carter Paul RutherfordEVP Commercial OpsMay 31Option Exercise33.8857,0921,934,021118,214Jun 02 04:35 PM
Carter Paul RutherfordEVP Commercial OpsMay 31Sale86.8557,0924,958,60061,122Jun 02 04:35 PM
MARTIN JOHN CExecutive ChairmanMay 02Option Exercise16.40100,0001,639,5004,119,727May 04 02:44 PM
MILLIGAN JOHN FPresident and CEOMay 02Option Exercise16.40112,0001,836,2401,170,963May 04 02:49 PM
Carter Paul RutherfordEVP Commercial OpsMay 02Option Exercise39.132,00078,25563,122May 04 04:23 PM
Carter Paul RutherfordEVP Commercial OpsMay 02Sale88.722,000177,44861,122May 04 04:23 PM
MILLIGAN JOHN FPresident and CEOMay 02Sale87.71112,0009,823,9541,058,963May 04 02:49 PM
MARTIN JOHN CExecutive ChairmanMay 02Sale87.82100,0008,781,6944,019,727May 04 02:44 PM
Alton Gregg HEVP, Corp & Med AffairsApr 19Option Exercise26.9935,874968,239177,964Apr 21 01:28 PM
Alton Gregg HEVP, Corp & Med AffairsApr 19Sale100.0140,0004,000,574137,964Apr 21 01:28 PM
MILLIGAN JOHN FPresident and CEOApr 04Option Exercise16.40112,0001,836,2401,170,963Apr 05 07:30 PM
MILLIGAN JOHN FPresident and CEOApr 04Sale94.59112,00010,593,9041,058,963Apr 05 07:30 PM
MARTIN JOHN CExecutive ChairmanApr 01Option Exercise16.40100,0001,639,5004,119,727Apr 05 07:49 PM
Carter Paul RutherfordEVP Commercial OpsApr 01Option Exercise24.912,00049,81063,122Apr 05 06:36 PM
Carter Paul RutherfordEVP Commercial OpsApr 01Sale91.342,000182,68061,122Apr 05 06:36 PM
MARTIN JOHN CExecutive ChairmanApr 01Sale93.24100,0009,323,5074,019,727Apr 05 07:49 PM
Alton Gregg HEVP, Corp & Med AffairsApr 01Sale91.235,000456,158142,090Apr 05 07:45 PM